Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
11.86 USD | +1.24% | +2.32% | +9.88% |
Apr. 18 | Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says | MT |
Apr. 18 | UK Regulator to Consider Undertakings for Theramex-Viatris Deal | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- One of the major weak points of the company is its financial situation.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+8.22% | 13.92B | C | ||
+33.43% | 700B | C+ | ||
+26.43% | 569B | B | ||
-5.12% | 358B | C+ | ||
+19.59% | 330B | B- | ||
+4.89% | 287B | C+ | ||
+14.32% | 236B | B+ | ||
+5.79% | 202B | B- | ||
-9.49% | 197B | A+ | ||
+4.26% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- VTRS Stock
- Ratings Viatris Inc.